HCV / Hepatitis

One promising proposal to greatly increase access to DAA HCV therapy is to keep this treatment with appropriately trained PCPs, in contrast with referring patients to infectious disease, gastroenterology, or hepatology subspecialists.

The phase 1/2 trial of a prime-boost vaccine to prevent chronic HCV infection was completed in an at-risk population of in people who inject drugs.

As outbreaks of vaccine-preventable diseases grow, it is important to review vaccination recommendations by age group.

Facing an outbreak of HAV, Arizona works to collaborate across public health departments and health care facilities.

Meeting goals to eliminate HIV, viral hepatitis, and sexually transmitted infections by 2030 will require accelerated efforts, according to a progress report from the WHO.

The state will allocate an additional $650,000 that will be divided up amongst areas of need.

Initiating a model that provides testing, treatment and linkage to care for HCV in correctional facilities would improve outcomes but requires a costly investment.

DONATE-HCV trial offers new hope to those on waiting lists for new hearts and/or lungs.

The FDA has approved Mavyret (glecaprevir and pibrentasvir) tablets to treat all 6 genotypes of hepatitis C in children 12 to 17 years.

A London study shows that men infected with HIV are acquiring HCV at much lower levels than before.

UK study in Addiction identifies benefits for controversial programs proposed as a solution for the ongoing opioid crisis.

A new analysis sheds light on what is needed to hit this benchmark.

Even when men who have sex with men are aware of the risk of hepatitis C infection, they aren’t always confident in their ability to go against the expectations of their peer group.

Patients with the hepatitis C virus who are on Medicaid in Oregon can expect to receive curative treatment in 2019, without having to wait for liver damage to set in.

Successful treatment of recently acquired hepatitis C virus infection in 8 weeks, with a regimen currently approved for 12 weeks, could enable shorter, less costly treatment.

Through retrospective analysis, investigators have identified a second case of rat hepatitis E virus in a human, which has close genetic relation to the first case.

People who inject drugs who are infected with hepatitis C virus can achieve sustained viral response, despite imperfect adherence, according to the results of a new trial.

A new approach to hepatitis C virus infection treatment could shave time and costs off the current standard regimen.

Research on nonalcoholic fatty liver disease in persons infected with HIV revealed a prevalence of the condition of about 40%, suggesting the condition may be an underappreciated comorbidity in this population.

A fixed-dose combination therapy (Vosevi, Gilead) was highly effective after 12 weeks in retreating direct-acting antiviral-experienced patients with hepatitis C virus infection, with and without HIV co-infection, including those with prior noncompletion of treatment or poor adherence.

A recent study by the Kirby Institute reported that after using direct-acting antiviral therapy 97% of participants with HCV who recently used injectable drugs achieved sustained viral response.

West Virginia’s Bureau for Public Health has requested the assistance from the CDC to contain the statewide hepatitis A outbreak.

New research from Johns Hopkins reveals that 2 genes, CMPK2 and BCLG, are selectively activated in the presence of type 1 interferon.

The results of a study published by JAMA Internal Medicine are a call to action for cities facing homelessness crises.

Small studies show good outcomes for previously uninfected recipients who receive kidneys from donors infected with hepatitis.

The combination of direct-acting antiviral agents glecaprevir/pibrentasvir (G/P), sofosbuvir, and ribavirin is now approved for new patient populations.

Millions with viral hepatitis go undiagnosed and untreated.

Suicide is a major problem for many patients with infectious diseases but pinpointing the exact cause has proven difficult.

An increase in injection drug use in the United States has augmented the likelihood of acquiring HCV, particularly genotype 3.

The new guidelines include updates on HCV management and testing in pregnant women, individuals who inject drugs, men who have sex with men, and individuals who are incarcerated.